CD274 and gastric cancer: Following this, the KEYNOTE-059 trial further explored pembrolizumab as a third-line treatment for GC or GEJC patients, reporting an overall response rate (ORR) of 22.7% in patients with a combined positive score (CPS) ≥ 1, compared to 8.6% in those with PD-L1-negative tumors.